Astrana Health (NASDAQ:ASTH – Get Free Report) had its price target boosted by equities research analysts at Truist Financial from $41.00 to $44.00 in a report issued on Friday, Benzinga reports. The brokerage presently has a “hold” rating on the stock. Truist Financial’s price objective suggests a potential downside of 2.31% from the stock’s current price.
Separately, Jefferies Financial Group assumed coverage on shares of Astrana Health in a research report on Monday. They issued a “buy” rating and a $50.00 price objective for the company.
Check Out Our Latest Research Report on ASTH
Astrana Health Price Performance
ASTH stock opened at $45.04 on Friday. The stock has a market cap of $2.62 billion, a price-to-earnings ratio of 34.12, a PEG ratio of 1.46 and a beta of 1.04. Astrana Health has a one year low of $28.86 and a one year high of $45.48. The company has a quick ratio of 2.35, a current ratio of 2.11 and a debt-to-equity ratio of 0.42.
Astrana Health (NASDAQ:ASTH – Get Free Report) last released its quarterly earnings results on Tuesday, February 27th. The company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.17 by $0.09. The business had revenue of $353.00 million during the quarter, compared to analyst estimates of $341.17 million. Astrana Health had a net margin of 4.49% and a return on equity of 11.52%. The company’s quarterly revenue was up 20.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.02 earnings per share. Equities research analysts expect that Astrana Health will post 1.35 earnings per share for the current year.
Astrana Health Company Profile
Apollo Medical Holdings, Inc engages in the provision of healthcare services. It offers integrated care, inpatient and physician alignment solutions. The company focuses on physicians providing high-quality medical care, population health management and care coordination for patients, particularly senior patients and patients with multiple chronic conditions.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Astrana Health, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Astrana Health wasn’t on the list.
While Astrana Health currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Click the link below and we’ll send you MarketBeat’s guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Source: marketbeat.com
